- Revenue of $394.1 million in the fourth quarter of 2022
increased 27.7% from revenue of $308.6 million for the comparable
prior-year period, representing a backlog conversion rate of
17.6%.
- Net new business awards were $485.1 million in the fourth
quarter of 2022, representing an increase of 5.8% from net new
business awards of $458.7 million for the comparable prior-year
period, which resulted in a net book-to-bill ratio of 1.23x.
- Fourth quarter of 2022 GAAP net income was $68.7 million, or
$2.12 per diluted share, versus GAAP net income of $50.0 million,
or $1.32 per diluted share, for the comparable prior-year period.
Net income margin was 17.4% and 16.2% for the fourth quarter of
2022 and 2021, respectively.
- EBITDA was $80.4 million for the fourth quarter of 2022, an
increase of 30.9% from EBITDA of $61.4 million for the comparable
prior-year period, resulting in an EBITDA margin of
20.4%.
Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today
announced financial results for the fourth quarter and full year
ended December 31, 2022.
Fourth Quarter 2022 Financial Results
Revenue for the three months ended December 31, 2022 increased
27.7% to $394.1 million, compared to $308.6 million for the
comparable prior-year period. On a constant currency organic basis,
revenue for the fourth quarter of 2022 increased 28.9% compared to
the fourth quarter of 2021.
Backlog as of December 31, 2022 increased 17.2% to $2,339.6
million from $1,997.1 million as of December 31, 2021. Net new
business awards were $485.1 million, representing a net
book-to-bill ratio of 1.23x for the fourth quarter of 2022, as
compared to $458.7 million for the comparable prior-year period.
The Company calculates the net book-to-bill ratio by dividing net
new business awards by revenue.
For the fourth quarter of 2022, total direct costs were $278.4
million, compared to total direct costs of $220.6 million in the
fourth quarter of 2021. Selling, general and administrative
(SG&A) expenses were $33.4 million in the fourth quarter of
2022, compared to SG&A expenses of $27.7 million in the fourth
quarter of 2021.
GAAP net income for the fourth quarter of 2022 was $68.7
million, or $2.12 per diluted share, versus GAAP net income of
$50.0 million, or $1.32 per diluted share, for the fourth quarter
of 2021. This resulted in a net income margin of 17.4% and 16.2%
for the fourth quarter of 2022 and 2021, respectively.
EBITDA for the fourth quarter of 2022 increased 30.9% to $80.4
million, or 20.4% of revenue, compared to $61.4 million, or 19.9%
of revenue, for the comparable prior-year period. On a constant
currency basis, EBITDA for the fourth quarter of 2022 increased
23.3% from the fourth quarter of 2021.
Full Year 2022 Financial Results
Revenue for the year ended December 31, 2022 increased 27.8% to
$1,460.0 million, compared to $1,142.4 million for the year ended
December 31, 2021. On a constant currency organic basis, revenue
increased 29.2% for the year ended December 31, 2022 compared to
the year ended December 31, 2021.
For the year ended December 31, 2022, net new business awards
were $1,829.5 million, representing a net book-to-bill ratio of
1.25x, compared to $1,610.4 million for the year ended December 31,
2021.
For the full year 2022, total direct costs were $1,027.6
million, compared to $814.2 million in the full year 2021. For the
full year 2022, SG&A expenses were $131.4 million, compared to
$108.4 million for the full year 2021.
GAAP net income for the full year 2022 was $245.4 million, or
$7.28 per diluted share, versus GAAP net income of $181.8 million,
or $4.81 per diluted share, for the full year 2021. This resulted
in a net income margin of 16.8% and 15.9% for the full year 2022
and 2021, respectively.
EBITDA for the full year 2022 increased 38.1% to $308.1 million,
or 21.1% of revenue, compared to $223.1 million, or 19.5% of
revenue, for the prior year. On a constant currency basis, EBITDA
increased 32.3% for the full year 2022 compared to the full year
2021.
A reconciliation of the Company’s non-GAAP financial measures,
including EBITDA and EBITDA margin to the corresponding GAAP
measures is provided below.
Balance Sheet and Liquidity
The Company’s Cash and cash equivalents were $28.3 million at
December 31, 2022, and the Company generated $136.7 million in cash
flow from operating activities during the fourth quarter of 2022.
The Company paid $89.7 million against the credit facility during
the fourth quarter of 2022. Short-term debt was $50.0 million at
December 31, 2022.
During the fourth quarter of 2022, the Company repurchased
228,247 shares at an average price of $206.68 per share for a total
of $47.2 million. For the full year 2022, the Company repurchased
approximately 5.7 million shares for $847.7 million. As of December
31, 2022, the Company had $452.8 million remaining under its
authorized share repurchase program.
2023 Financial Guidance
The Company forecasts 2023 revenue in the range of $1.690
billion to $1.750 billion, representing growth of 15.8% to 19.9%
over 2022 revenue of $1.460 billion. GAAP net income for full year
2023 is forecasted in the range of $245.0 million to $265.0
million. Additionally, full year 2023 EBITDA is expected in the
range of $325.0 million to $350.0 million. Based on forecasted 2023
revenue of $1.690 billion to $1.750 billion and GAAP net income of
$245.0 million to $265.0 million, diluted earnings per share (GAAP)
is forecasted in the range of $7.53 to $8.14. This guidance assumes
a full year 2023 tax rate of 17.5% to 18.5% and does not reflect
the potential impact of any share repurchases the Company may make
pursuant to the share repurchase program after December 31,
2022.
Conference Call Details
Medpace will host a conference call at 9:00 a.m. ET, Tuesday,
February 14, 2023, to discuss its fourth quarter and full year 2022
results.
To participate in the conference call, interested parties must
register in advance by clicking on this link. While it is not
required, it is recommended you join 10 minutes prior to the event
start. Upon registration, all telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number along with a unique PIN that can be
used to access the call.
To access the conference call via webcast, visit the “Investors”
section of Medpace’s website at medpace.com. The webcast replay of
the call will be available at the same site approximately one hour
after the end of the call. A supplemental slide presentation will
also be available at the “Investors” section of Medpace’s website
prior to the start of the call.
About Medpace
Medpace is a scientifically-driven, global, full-service
clinical contract research organization (CRO) providing Phase I-IV
clinical development services to the biotechnology, pharmaceutical
and medical device industries. Medpace’s mission is to accelerate
the global development of safe and effective medical therapeutics
through its high-science and disciplined operating approach that
leverages regulatory and therapeutic expertise across all major
areas including oncology, cardiology, metabolic disease,
endocrinology, central nervous system and anti-viral and
anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs
approximately 5,200 people across 40 countries as of December 31,
2022.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation,
statements regarding our forecasted financial results and the
effective tax rate used for non-GAAP adjustment purposes. In this
context, forward-looking statements often address expected future
business and financial performance and financial condition, and
often contain words such as “guidance,” “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,”
“target,” “forecast,” “may,” “could,” “likely,” “anticipate,”
“project,” “goal,” “objective,” “potential,” “range,” “estimate,”
“preliminary,” similar expressions, and variations or negatives of
these words.
These forward-looking statements are based on management’s
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our financial condition,
actual results, performance (including share price performance), or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, the
following: the potential loss, delay or non-renewal of our
contracts, or the non-payment by customers for services we have
performed; the failure to convert backlog to revenue at our present
or historical conversion rate(s); the failure to maintain or
generate new business awards; fluctuation in our results between
fiscal quarters and years; the risks and uncertainties related to
disruptions to or reductions in business operations or prospects
due to pandemics, epidemics, widespread health emergencies, or
outbreaks of infectious diseases such as coronavirus disease
COVID-19; decreased operating margins due to increased pricing
pressure or other factors; our failure to perform our services in
accordance with contractual requirements, government regulations
and ethical considerations; the impact of underpricing our
contracts, overrunning our cost estimates or failing to receive
approval for or experiencing delays with documentation of change
orders; our failure to increase our market share, grow our
business, successfully execute our growth strategies or manage our
growth effectively; the impact of a failure to retain key
executives or other personnel or recruit experienced personnel; the
risks associated with our information systems infrastructure,
including potential cybersecurity breaches and other disruptions
which could compromise patient information or our information;
adverse results from customer or therapeutic area concentration;
the risks associated with doing business internationally, including
the effects of tariffs and trade wars; the risks associated with
the Foreign Corrupt Practices Act and other anti-corruption laws;
future net losses; the impact of changes in tax laws and
regulations; our failure to attract suitable investigators and
patients to our clinical trials; the liability risks associated
with our research and development services, including risks of
liability resulting from harm to patients; inadequate insurance
coverage for our operations and indemnification obligations;
fluctuations in exchange rates; general economic conditions,
including inflation, in the markets in which we operate, including
financial market conditions; the impact of unfavorable economic
conditions, including conditions caused by the uncertain
international economic environment and current and future
international conflicts; the impact of a natural disaster or other
catastrophic event; negative outsourcing trends in the
biopharmaceutical industry and a reduction in aggregate
expenditures and research and development budgets; our inability to
compete effectively with other CROs; the impact of healthcare
reform; the impact of consolidation in the biopharmaceutical
industry; our failure to comply with federal, state and foreign
healthcare laws; the effect of current and proposed laws and
regulations regarding the protection of personal data; our
potential involvement in costly intellectual property lawsuits;
actions by regulatory authorities or customers to limit the scope
of indications related to or withdraw an approved drug, biologic or
medical device from the market; and the impact of industry-wide
reputational harm to CROs.
These and other important factors discussed under the caption
“Risk Factors” in our Annual Report on Form 10-K filed with the
Securities and Exchange Commission, or SEC, and our other reports
filed with the SEC could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. We cannot guarantee that any forward-looking
statement will be realized. Achievement of anticipated results is
subject to substantial risks, uncertainties and inaccurate
assumptions. If known or unknown risks or uncertainties materialize
or if underlying assumptions prove inaccurate, actual results could
vary materially from past results and those anticipated, estimated
or projected. These factors should not be construed as exhaustive
and should be read in conjunction with the other cautionary
statements that are included in this release and in our filings
with the SEC. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events, developments or circumstances cause our views to
change. These forward-looking statements should not be relied upon
as representing our views as of any date subsequent to the date of
this press release.
Non-GAAP Financial Measures
Certain financial measures presented in this press release, such
as EBITDA and EBITDA margin, are not recognized under generally
accepted accounting principles in the United States of America, or
U.S. GAAP. Management uses EBITDA and EBITDA margin or comparable
metrics as a measurement used in evaluating our operating
performance on a consistent basis, as a consideration to assess
incentive compensation for our employees, for planning purposes,
including the preparation of our internal annual operating budget,
and to evaluate the performance and effectiveness of our
operational strategies.
EBITDA and EBITDA margin have important limitations as
analytical tools and you should not consider them in isolation, or
as a substitute for, analysis of our results as reported under U.S.
GAAP. See the condensed consolidated financial statements included
elsewhere in this release for our U.S. GAAP results. Additionally,
for reconciliations of EBITDA and EBITDA margin to our closest
reported U.S. GAAP measures, refer to the appendix of this press
release.
We believe that EBITDA and EBITDA margin are useful to provide
additional information to investors about certain material non-cash
and non-recurring items. While we believe these financial measures
are commonly used by investors to evaluate our performance and that
of our competitors, because not all companies use identical
calculations, this presentation of EBITDA and EBITDA margin may not
be comparable to other similarly titled measures of other companies
and should not be considered as an alternative to performance
measures derived in accordance with U.S. GAAP. EBITDA is calculated
as net income attributable to Medpace Holdings, Inc. before income
tax expense, interest expense, net, depreciation and amortization.
EBITDA margin is calculated by dividing EBITDA by Revenue, net for
each period. Our presentation of EBITDA and EBITDA margin should
not be construed as an inference that our future results will be
unaffected by unusual or non-recurring items.
MEDPACE HOLDINGS, INC. AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
OPERATIONS
(Unaudited)
(Amounts in thousands, except per share
amounts)
Three Months Ended December
31,
Twelve Months Ended December
31,
2022
2021
2022
2021
Revenue, net
$
394,098
$
308,552
$
1,459,996
$
1,142,377
Operating expenses:
Direct service costs, excluding
depreciation and amortization
140,687
118,930
534,887
441,090
Reimbursed out-of-pocket expenses
137,680
101,638
492,671
373,132
Total direct costs
278,367
220,568
1,027,558
814,222
Selling, general and administrative
33,401
27,664
131,400
108,421
Depreciation
5,061
4,186
18,989
16,005
Amortization
838
1,279
3,352
5,114
Total operating expenses
317,667
253,697
1,181,299
943,762
Income from operations
76,431
54,855
278,697
198,615
Other income, net:
Miscellaneous (expense) income, net
(1,959
)
1,089
7,068
3,342
Interest expense, net
(827
)
(23
)
(2,905
)
(105
)
Total other (expense) income, net
(2,786
)
1,066
4,163
3,237
Income before income taxes
73,645
55,921
282,860
201,852
Income tax provision
4,975
5,887
37,492
20,004
Net income
$
68,670
$
50,034
$
245,368
$
181,848
Net income per share attributable to
common
Basic
$
2.20
$
1.39
$
7.57
$
5.06
Diluted
$
2.12
$
1.32
$
7.28
$
4.81
Weighted average common shares
outstanding:
Basic
31,192
35,979
32,388
35,862
Diluted
32,423
37,741
33,671
37,697
MEDPACE HOLDINGS, INC. AND
SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share
amounts)
As Of December 31,
2022
2021
ASSETS
Current assets:
Cash and cash equivalents
$
28,265
$
461,304
Accounts receivable and unbilled, net
253,404
186,432
Prepaid expenses and other current
assets
52,293
43,176
Total current assets
333,962
690,912
Property and equipment, net
109,849
93,153
Operating lease right-of-use assets
139,068
129,558
Goodwill
662,396
662,396
Intangible assets, net
38,008
41,360
Deferred income taxes
48,083
25,134
Other assets
21,129
17,422
Total assets
$
1,352,495
$
1,659,935
LIABILITIES AND SHAREHOLDERS’
EQUITY
Current liabilities:
Accounts payable
$
33,069
$
25,678
Accrued expenses
210,125
159,286
Advanced billings
462,729
344,641
Short-term debt
50,000
—
Other current liabilities
47,547
27,612
Total current liabilities
803,470
557,217
Operating lease liabilities
138,867
130,965
Deferred income tax liability
1,070
1,080
Other long-term liabilities
22,701
17,745
Total liabilities
966,108
707,007
Commitments and contingencies
Shareholders’ equity:
Preferred stock - $0.01 par-value;
5,000,000 shares authorized; no shares issued and outstanding at
December 31, 2022 and 2021, respectively
—
—
Common stock - $0.01 par-value;
250,000,000 shares authorized at December 31, 2022 and 2021,
respectively; 31,091,694 and 36,006,778 shares issued and
outstanding at December 31, 2022 and 2021, respectively
309
360
Treasury stock - 71,573 and 180,000 shares
at December 31, 2022 and 2021, respectively
(12,497
)
(5,427
)
Additional paid-in capital
770,794
727,857
(Accumulated deficit) Retained
earnings
(359,827
)
234,984
Accumulated other comprehensive loss
(12,392
)
(4,846
)
Total shareholders’ equity
386,387
952,928
Total liabilities and shareholders’
equity
$
1,352,495
$
1,659,935
MEDPACE HOLDINGS, INC. AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH
FLOWS
(Amounts in thousands)
Twelve Months Ended December
31,
2022
2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
$
245,368
$
181,848
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation
18,989
16,005
Amortization
3,352
5,114
Stock-based compensation expense
21,412
14,469
Noncash lease expense
18,015
16,288
Deferred income tax benefit
(23,014
)
(37,112
)
Amortization and adjustment of deferred
credit
(620
)
(668
)
Other
(1,507
)
676
Changes in assets and liabilities:
Accounts receivable and unbilled, net
(66,920
)
(24,982
)
Prepaid expenses and other current
assets
(10,175
)
(9,134
)
Accounts payable
6,431
1,866
Accrued expenses
52,476
26,156
Advanced billings
118,088
88,977
Lease liabilities
(15,899
)
(15,632
)
Other assets and liabilities, net
22,054
(544
)
Net cash provided by operating
activities
388,050
263,327
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures
(36,879
)
(28,271
)
Other
(1,863
)
(3,093
)
Net cash used in investing activities
(38,742
)
(31,364
)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercises
22,074
17,643
Repurchases of common stock
(847,849
)
(62,096
)
Proceeds from revolving loan
324,200
—
Payments on revolving loan
(274,200
)
—
Net cash used in financing activities
(775,775
)
(44,453
)
EFFECT OF EXCHANGE RATES ON CASH, CASH
EQUIVALENTS, AND RESTRICTED CASH
(6,572
)
(3,972
)
(DECREASE) INCREASE IN CASH, CASH
EQUIVALENTS, AND RESTRICTED CASH
(433,039
)
183,538
CASH, CASH EQUIVALENTS, AND RESTRICTED
CASH — Beginning of period
461,304
277,766
CASH, CASH EQUIVALENTS, AND RESTRICTED
CASH — End of period
$
28,265
$
461,304
MEDPACE HOLDINGS, INC. AND
SUBSIDIARIES
RECONCILIATION OF NON-GAAP MEASURES
(UNAUDITED)
(Amounts in thousands)
Three Months Ended December
31,
Twelve Months Ended December
31,
2022
2021
2022
2021
RECONCILIATION OF GAAP NET INCOME TO
EBITDA
Net income (GAAP)
$
68,670
$
50,034
$
245,368
$
181,848
Interest expense, net
827
23
2,905
105
Income tax provision
4,975
5,887
37,492
20,004
Depreciation
5,061
4,186
18,989
16,005
Amortization
838
1,279
3,352
5,114
EBITDA (Non-GAAP)
$
80,371
$
61,409
$
308,106
$
223,076
Net income margin (GAAP)
17.4
%
16.2
%
16.8
%
15.9
%
EBITDA margin (Non-GAAP)
20.4
%
19.9
%
21.1
%
19.5
%
FY 2023 GUIDANCE RECONCILIATION
(UNAUDITED)
(Amounts in millions, except per share
amounts)
Forecast 2023
Net Income
Net income per diluted
share
Low
High
Low
High
Net income and net income per diluted
share (GAAP)
$
245.0
$
265.0
$
7.53
$
8.14
Income tax provision
55.0
60.0
Interest income, net
(1.4
)
(1.4
)
Depreciation
24.2
24.2
Amortization
2.2
2.2
EBITDA (Non-GAAP)
$
325.0
$
350.0
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230213005450/en/
Investor Contact: Lauren Morris 513.579.9911 x11994
l.morris@medpace.com
Media Contact: Julie Hopkins 513.579.9911 x12627
j.hopkins@medpace.com
Medpace (NASDAQ:MEDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Medpace (NASDAQ:MEDP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024